{
  "id": 5695813,
  "title": "BioCardia CEO Peter Altman buys $872 in company stock",
  "url": "https://urgent.news/2026/09/05/biocardia-ceo-peter-altman-buys-872-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-05T02:01:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/biocardia-ceo-peter-altman-buys-872-in-company-stock-93CH-4890147"
  },
  "original_language": "en",
  "account": null,
  "summary": "BioCardia CEO Peter Altman has recently increased his stake in the company by purchasing 800 shares of BioCardia common stock, valued at $872. The transactions took place at prices ranging from $1.09 to $1.10 per share, with a weighted average price of $1.09. This purchase comes as the stock trades at $1.08, down approximately 48% over the past year. Despite this decline, InvestingPro analysis suggests the stock is currently undervalued. Following these transactions, Mr. Altman directly holds 381,985 shares of BioCardia common stock. The company maintains a solid financial health rating with liquid assets exceeding short-term obligations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}